Literature DB >> 26299867

[DNA methylation in the promoter regions of the laminin family genes in normal and breast carcinoma tissues].

O A Simonova1, E B Kuznetsova1,2, E V Poddubskaya3, T V Kekeeva1, R A Kerimov3, I D Trotsenko4, A S Tanas1,2,5, V V Rudenko1,2, E A Alekseeva1,2, D V Zaletayev1,2,5, V V Strelnikov1,2,5,6.   

Abstract

Extracellular glycoproteins of the laminin family are essential components of basement membranes involved in a number of biological processes, including tissue differentiation, wound healing, and tumorigenesis. We present the first comprehensive study of promoter methylation status of the genes encoding laminin chains in normal tissues (peripheral blood leucocytes, buccal epithelial cells, autopsy breast tissue samples) and in breast carcinoma samples. Based on the results of this study, we divide laminin genes into three categories. Genes, constitutively methylated in breast tissues include LAMA3A, LAMB2, LAMB3, and LAMC2. Genes prone to abnormal methylation in breast carcinoma include LAMA1, LAMA2, LAMA3B, LAMA4, LAMB1, and LAMC3. Genes that are rarely if ever methylated in breast carcinoma include LAMA5 and LAMC1. The constitutively methylated group includes all of the genes that encode subunits of laminin-5 (the historical name of laminin 332), the promoters of which were previously considered unmethylated in normal tissues and prone to abnormal methylation in breast cancer.

Entities:  

Keywords:  DNA methylation; breast cancer; laminin

Year:  2015        PMID: 26299867     DOI: 10.7868/S0026898415040163

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  6 in total

Review 1.  Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Authors:  Yunchun Zhao; Xiaoling Zheng; Yongquan Zheng; Yue Chen; Weidong Fei; Fengmei Wang; Caihong Zheng
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

2.  Integrative analysis with expanded DNA methylation data reveals common key regulators and pathways in cancers.

Authors:  Shicai Fan; Jianxiong Tang; Nan Li; Ying Zhao; Rizi Ai; Kai Zhang; Mengchi Wang; Wei Du; Wei Wang
Journal:  NPJ Genom Med       Date:  2019-02-01       Impact factor: 8.617

3.  Abnormal promoter DNA hypermethylation of the integrin, nidogen, and dystroglycan genes in breast cancer.

Authors:  Vladimir V Strelnikov; Ekaterina B Kuznetsova; Alexander S Tanas; Viktoria V Rudenko; Alexey I Kalinkin; Elena V Poddubskaya; Tatiana V Kekeeva; Galina G Chesnokova; Ivan D Trotsenko; Sergey S Larin; Sergey I Kutsev; Dmitry V Zaletaev; Marina V Nemtsova; Olga A Simonova
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

Review 4.  The Role of Extracellular Matrix Proteins in Breast Cancer.

Authors:  Arkadiusz Lepucki; Kinga Orlińska; Aleksandra Mielczarek-Palacz; Jacek Kabut; Pawel Olczyk; Katarzyna Komosińska-Vassev
Journal:  J Clin Med       Date:  2022-02-25       Impact factor: 4.241

5.  Abnormal Hypermethylation of CpG Dinucleotides in Promoter Regions of Matrix Metalloproteinases Genes in Breast Cancer and Its Relation to Epigenomic Subtypes and HER2 Overexpression.

Authors:  Olga A Simonova; Ekaterina B Kuznetsova; Alexander S Tanas; Viktoria V Rudenko; Elena V Poddubskaya; Tatiana V Kekeeva; Ivan D Trotsenko; Sergey S Larin; Sergei I Kutsev; Dmitry V Zaletaev; Marina V Nemtsova; Vladimir V Strelnikov
Journal:  Biomedicines       Date:  2020-05-10

6.  Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.

Authors:  Ching-Wen Chou; Yu-Min Huang; Yu-Jia Chang; Chien-Yu Huang; Chin-Sheng Hung
Journal:  Int J Med Sci       Date:  2021-04-26       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.